Poviztra 0.25 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml

Poviztra 0.25 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml is used for chronic weight management in adults. It is prescribed alongside a reduced-calorie diet and increased physical activity to help achieve and maintain weight loss in patients with obesity or those who have weight-related health conditions.

Poviztra 0.25 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml contains semaglutide, a GLP-1 receptor agonist that mimics a natural hormone involved in appetite regulation. It works by slowing down gastric emptying, increasing the feeling of fullness, and reducing food cravings, which helps lower overall calorie intake.

In some cases, Poviztra 0.25 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml may cause side effects such as nausea, vomiting, diarrhoea, constipation, abdominal discomfort, dizziness, or altered taste. Talk to your doctor if the side effects persist or worsen.

Poviztra 0.25 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml should also not be used during pregnancy, while breastfeeding, or in children under 12 years of age. The pen contains 4 doses, designed to provide coverage for an entire month since it is administered once weekly.

Poviztra 0.25 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml is used to treat various medical conditions. The detailed uses are as follows:

• Chronic weight management: Used in adults with obesity or overweight with associated comorbidities to help achieve and maintain long-term weight loss.
• Cardiovascular risk reduction: Used to lower the risk of major adverse cardiovascular events such as heart attack or stroke in adults with obesity or overweight and established heart disease.

• A qualified healthcare professional will instruct you on how to administer Poviztra 0.25 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml. 
• It is a once-weekly subcutaneous injection in the abdomen, thigh, or upper arm. It should not be injected intravenously or intramuscularly. 
• Kindly do not self-administer without proper training and medical guidance.

• Poviztra 0.25 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml contains semaglutide, a GLP-1 receptor agonist that mimics a natural hormone responsible for regulating appetite and digestion.
• It helps reduce calorie intake by slowing gastric emptying, increasing feelings of fullness, and decreasing hunger and food cravings, thereby supporting weight loss.
• Promotes long-term weight management when combined with a reduced-calorie diet and physical activity, helping patients achieve and maintain a healthy body weight.
• Improves metabolic health by aiding in better blood sugar control, lowering cholesterol levels, and reducing blood pressure in patients with obesity or overweight.
• Reduces cardiovascular risk by lowering the chance of major heart-related events (such as heart attack or stroke) in adults with established heart disease who are overweight or obese.

• Do not use Poviztra 0.25 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml if you or a close family member has ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC), if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or if you have ever experienced a severe allergic reaction to semaglutide or any of its ingredients.
• Let your doctor know about all your medical conditions before using Poviztra 0.25 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml, including if you have or have ever had pancreatitis (inflamed pancreas), gallbladder problems or gallstones, kidney disease, severe digestive issues like gastroparesis (slow stomach emptying), diabetic eye disease (retinopathy), or any mental health concerns such as depression or suicidal thoughts.
• Inform your doctor about every medicine, vitamin, or herbal supplement you are taking, as Poviztra 0.25 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml may change how other medicines are absorbed. For instance, using Poviztra 0.25 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml with insulin or sulfonylureas can increase the risk of low blood sugar, so your doctor may need to adjust other treatments.
• Do not use Poviztra 0.25 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml if you are pregnant, planning pregnancy, or breastfeeding. Stop the medicine at least 2 months before trying to conceive due to its long-lasting effect in the body. If you find out you are pregnant while using Poviztra 0.25 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml, stop it immediately and call your doctor.
• Poviztra 0.25 mg Flextouch Prefilled Pen Injection Combipack 1.5 ml is not recommended for children under 12 years old, because its safety has not been fully established.
• Contact your doctor immediately if you experience any severe or persistent side effects, such as ongoing stomach pain (which may signal pancreatitis), signs of an allergic reaction (swelling, rash, difficulty breathing), severe vomiting or diarrhoea leading to dehydration, or mood changes such as depression or suicidal thoughts.